Literature DB >> 23731188

Tetraspanins as regulators of the tumour microenvironment: implications for metastasis and therapeutic strategies.

S Detchokul1, E D Williams, M W Parker, A G Frauman.   

Abstract

UNLABELLED: One of the hallmarks of cancer is the ability to activate invasion and metastasis. Cancer morbidity and mortality are largely related to the spread of the primary, localized tumour to adjacent and distant sites. Appropriate management and treatment decisions based on predicting metastatic disease at the time of diagnosis is thus crucial, which supports better understanding of the metastatic process. There are components of metastasis that are common to all primary tumours: dissociation from the primary tumour mass, reorganization/remodelling of extracellular matrix, cell migration, recognition and movement through endothelial cells and the vascular circulation and lodgement and proliferation within ectopic stroma. One of the key and initial events is the increased ability of cancer cells to move, escaping the regulation of normal physiological control. The cellular cytoskeleton plays an important role in cancer cell motility and active cytoskeletal rearrangement can result in metastatic disease. This active change in cytoskeletal dynamics results in manipulation of plasma membrane and cellular balance between cellular adhesion and motility which in turn determines cancer cell movement. Members of the tetraspanin family of proteins play important roles in regulation of cancer cell migration and cancer-endothelial cell interactions, which are critical for cancer invasion and metastasis. Their involvements in active cytoskeletal dynamics, cancer metastasis and potential clinical application will be discussed in this review. In particular, the tetraspanin member, CD151, is highlighted for its major role in cancer invasion and metastasis. LINKED ARTICLES: This article is part of a themed section on Cytoskeleton, Extracellular Matrix, Cell Migration, Wound Healing and Related Topics. To view the other articles in this section visit http://dx.doi.org/10.1111/bph.2014.171.issue-24.
© 2013 The British Pharmacological Society.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 23731188      PMCID: PMC4290697          DOI: 10.1111/bph.12260

Source DB:  PubMed          Journal:  Br J Pharmacol        ISSN: 0007-1188            Impact factor:   8.739


  352 in total

1.  Involvement of alpha3 integrin/tetraspanin complexes in the angiogenic response induced by angiotensin II.

Authors:  C Domínguez-Jiménez; M Yáñez-Mó; A Carreira; R Tejedor; R González-Amaro; V Alvarez; F Sánchez-Madrid
Journal:  FASEB J       Date:  2001-06       Impact factor: 5.191

2.  Can mutations in gamma-actin modulate the toxicity of microtubule targeting agents?

Authors:  Tito Fojo
Journal:  J Natl Cancer Inst       Date:  2006-10-04       Impact factor: 13.506

3.  Homophilic interactions of Tetraspanin CD151 up-regulate motility and matrix metalloproteinase-9 expression of human melanoma cells through adhesion-dependent c-Jun activation signaling pathways.

Authors:  In-Kee Hong; Young-June Jin; Hee-Jung Byun; Doo-Il Jeoung; Young-Myeong Kim; Hansoo Lee
Journal:  J Biol Chem       Date:  2006-06-23       Impact factor: 5.157

4.  Expression and function of transmembrane-4 superfamily (tetraspanin) proteins in osteoclasts: reciprocal roles of Tspan-5 and NET-6 during osteoclastogenesis.

Authors:  Kaori Iwai; Masaru Ishii; Shiro Ohshima; Kunio Miyatake; Yukihiko Saeki
Journal:  Allergol Int       Date:  2007-11-01       Impact factor: 5.836

5.  Complementary DNA arrays identify CD63 tetraspanin and alpha3 integrin chain as differentially expressed in low and high metastatic human colon carcinoma cells.

Authors:  Isabelle Sordat; Charles Decraene; Timothée Silvestre; Olivier Petermann; Charles Auffray; Geneviève Piétu; Bernard Sordat
Journal:  Lab Invest       Date:  2002-12       Impact factor: 5.662

6.  Integrin alpha4beta1 signaling is required for lymphangiogenesis and tumor metastasis.

Authors:  Barbara Garmy-Susini; Christie J Avraamides; Michael C Schmid; Philippe Foubert; Lesley G Ellies; Leo Barnes; Chloe Feral; Thalia Papayannopoulou; Andrew Lowy; Sarah L Blair; David Cheresh; Mark Ginsberg; Judith A Varner
Journal:  Cancer Res       Date:  2010-04-13       Impact factor: 12.701

7.  The 4F9 antigen is a member of the tetra spans transmembrane protein family and functions as an accessory molecule in T cell activation and adhesion.

Authors:  Y Nojima; T Hirose; K Tachibana; T Tanaka; L Shi; J Doshen; G J Freeman; S F Schlossman; C Morimoto
Journal:  Cell Immunol       Date:  1993-11       Impact factor: 4.868

8.  MT1-MMP collagenolytic activity is regulated through association with tetraspanin CD151 in primary endothelial cells.

Authors:  María Yañez-Mó; Olga Barreiro; Pilar Gonzalo; Alicia Batista; Diego Megías; Laura Genís; Norman Sachs; Mónica Sala-Valdés; Miguel A Alonso; María C Montoya; Arnoud Sonnenberg; Alicia G Arroyo; Francisco Sánchez-Madrid
Journal:  Blood       Date:  2008-07-28       Impact factor: 22.113

9.  alpha5beta1 Integrin blockade inhibits lymphangiogenesis in airway inflammation.

Authors:  Tatsuma Okazaki; Amy Ni; Oluwasheyi A Ayeni; Peter Baluk; Li-Chin Yao; Doerte Vossmeyer; Gunther Zischinsky; Grit Zahn; Jochen Knolle; Claudia Christner; Donald M McDonald
Journal:  Am J Pathol       Date:  2009-05-14       Impact factor: 4.307

10.  Regulation of endothelial cell motility by complexes of tetraspan molecules CD81/TAPA-1 and CD151/PETA-3 with alpha3 beta1 integrin localized at endothelial lateral junctions.

Authors:  M Yáñez-Mó; A Alfranca; C Cabañas; M Marazuela; R Tejedor; M A Ursa; L K Ashman; M O de Landázuri; F Sánchez-Madrid
Journal:  J Cell Biol       Date:  1998-05-04       Impact factor: 10.539

View more
  37 in total

1.  Editorial: cell movement.

Authors:  S Detchokul; A G Frauman
Journal:  Br J Pharmacol       Date:  2014-12       Impact factor: 8.739

Review 2.  Tetraspanins in cell migration.

Authors:  Xupin Jiang; Jiaping Zhang; Yuesheng Huang
Journal:  Cell Adh Migr       Date:  2015-06-19       Impact factor: 3.405

3.  Loci-specific differences in blood DNA methylation in HBV-negative populations at risk for hepatocellular carcinoma development.

Authors:  Katarzyna Lubecka; Kirsty Flower; Megan Beetch; Jay Qiu; Lucinda Kurzava; Hannah Buvala; Adam Ruhayel; Samer Gawrieh; Suthat Liangpunsakul; Tracy Gonzalez; George McCabe; Naga Chalasani; James M Flanagan; Barbara Stefanska
Journal:  Epigenetics       Date:  2018-07-30       Impact factor: 4.528

4.  Prognostic significance of Tspan9 in gastric cancer.

Authors:  Tongtong Feng; Libin Sun; Weiwei Qi; Fei Pan; Jing Lv; Jing Guo; Shufen Zhao; Aiping Ding; Wensheng Qiu
Journal:  Mol Clin Oncol       Date:  2016-07-15

Review 5.  Extracellular Vesicle-Mediated Bone Remodeling and Bone Metastasis: Implications in Prostate Cancer.

Authors:  Kalyani C Patil; Carolina Soekmadji
Journal:  Subcell Biochem       Date:  2021

6.  KRAS Addiction Promotes Cancer Cell Adaptation in Harsh Microenvironment Through Macropinocytosis.

Authors:  Laetitia Seguin
Journal:  Subcell Biochem       Date:  2022

7.  TSPAN8 promotes gastric cancer growth and metastasis via ERK MAPK pathway.

Authors:  Lunshou Wei; Yan Li; Zhimin Suo
Journal:  Int J Clin Exp Med       Date:  2015-06-15

8.  CellectSeq: In silico discovery of antibodies targeting integral membrane proteins combining in situ selections and next-generation sequencing.

Authors:  Abdellali Kelil; Eugenio Gallo; Sunandan Banerjee; Jarrett J Adams; Sachdev S Sidhu
Journal:  Commun Biol       Date:  2021-05-12

9.  Exosomal Protease Cargo as Prognostic Biomarker in Colorectal Cancer.

Authors:  Natalia V Yunusova; Elena A Zambalova; Marina R Patysheva; Elena S Kolegova; Sergey G Afanas'ev; Olga V Cheremisina; Alina E Grigor'eva; Svetlana N Tamkovich; Irina V Kondakova
Journal:  Asian Pac J Cancer Prev       Date:  2021-03-01

10.  CD9-positive cells in the intermediate lobe migrate into the anterior lobe to supply endocrine cells.

Authors:  K Horiguchi; K Fujiwara; T Tsukada; T Nakakura; S Yoshida; R Hasegawa; S Takigami; S Ohsako
Journal:  Histochem Cell Biol       Date:  2021-06-29       Impact factor: 4.304

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.